GlaxoSmithKline CEO Emma Walmsley has reportedly received a pay cut of 14 per cent after the company missed an internal profit target for sales of routine vaccinations against other diseases.
According the pharmaceutical giant’s annual report, Ms Walmsley’s total remuneration for 2020 came in at seven million pounds (€8.2 million).
The cut, according to comments by Non-Executive Director Urs Rohner in the report, partly reflected a missed internal profit target for biopharmaceuticals, mainly due to lockdowns stopping people from receiving routine vaccinations which cut into the CEO’s bonus.
Ms Walmsley was appointed CEO in 2017, and has made great strides in the company’s restructuring efforts, as it works to split its consumer and pharmaceutical businesses.
GlaxoSmithKline has been among the frontrunners in the effort to develop COVID-19 vaccines and treatments, with the company’s offering, which was developed in conjunction with the University of Oxford, having been approved for use in over 50 countries.
Last month, pharmaceutical chiefs came under fire as EU leaders prioritised the acceleration of COVID-19 vaccination rollouts, with pharmaceutical companies being pressed to abide by delivery commitments.
byteEDGE founder Akash Gupt shares lessons from taking Enterprise AI global
Four years into building Enterprise AI SaaS company byteEDGE, founder Akash Gupt says the journey has been “an ocean of ...
Valletta summit ‘an opportunity to show Malta’s unique heritage’ – WTTC President Gloria Guevara
MTA joins the World Travel and Tourism Council as a Destination Partner ahead of the WTTC Global Summit 2026.
Affordable EVs, Government incentives fuel growth of electric passenger cars, autodealers say
'The arrival of more competitively priced electric models has broadened the appeal of the technology,' CEO says.
What CEOs can learn from Dolly Parton’s approach to business
Behind the rhinestones, high blonde hair and Tennessee accent, there was a true businesswoman.
